|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
44,800,000 |
Market
Cap: |
153.22(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.4 - $9.48 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Kodiak Sciences is a biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer conjugate for the treatment in retinal vascular diseases including wet age-related macular degeneration (AMD), diabetic macular edema and retinal vein occlusion. Co.'s pipeline, including product candidates KSI-501 and KSI-601, are used for other needs in retina such as dry AMD and glaucoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,379,445 |
Total Buy Value |
$0 |
$0 |
$0 |
$9,508,745 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
9 |
Total Shares Sold |
0 |
0 |
7,587 |
15,417 |
Total Sell Value |
$0 |
$0 |
$70,517 |
$126,006 |
Total People Sold |
0 |
0 |
2 |
2 |
Total Sell Transactions |
0 |
0 |
4 |
8 |
End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baker Julian |
Director |
|
2021-09-16 |
4 |
B |
$94.59 |
$109,064 |
I/I |
1,153 |
13,300,993 |
2.25 |
-47% |
|
Baker Julian |
Director |
|
2021-09-15 |
4 |
B |
$94.38 |
$2,896,216 |
I/I |
30,685 |
13,299,840 |
2.25 |
-42% |
|
Baker Julian |
Director |
|
2021-09-07 |
4 |
B |
$92.88 |
$5,365,227 |
I/I |
57,501 |
13,269,155 |
2.25 |
-36% |
|
Ehrlich Jason |
See Remarks |
|
2021-08-20 |
4 |
AS |
$88.17 |
$635,534 |
D/D |
(6,950) |
51,541 |
|
-7% |
|
Ehrlich Jason |
See Remarks |
|
2021-08-20 |
4 |
OE |
$10.29 |
$54,105 |
D/D |
5,258 |
58,491 |
|
- |
|
Baker Julian |
Director |
|
2021-08-19 |
4 |
B |
$86.94 |
$7,323,898 |
I/I |
83,648 |
13,211,654 |
2.25 |
1% |
|
Baker Julian |
Director |
|
2021-08-18 |
4 |
B |
$87.79 |
$1,984,806 |
I/I |
22,584 |
13,128,006 |
2.25 |
0% |
|
Baker Julian |
Director |
|
2021-08-17 |
4 |
B |
$84.80 |
$701,254 |
I/I |
8,164 |
13,105,422 |
2.25 |
2% |
|
Baker Julian |
Director |
|
2021-08-13 |
4 |
B |
$88.59 |
$3,392,579 |
I/I |
38,264 |
13,097,258 |
2.25 |
7% |
|
Baker Julian |
Director |
|
2021-08-12 |
4 |
B |
$85.58 |
$958,954 |
I/I |
10,986 |
13,058,994 |
2.25 |
7% |
|
Baker Julian |
Director |
|
2021-08-11 |
4 |
B |
$84.39 |
$4,609,090 |
I/I |
53,523 |
13,048,008 |
2.25 |
7% |
|
Ehrlich Jason |
See Remarks |
|
2021-07-20 |
4 |
AS |
$85.76 |
$599,624 |
D/D |
(6,950) |
53,233 |
|
16% |
|
Baker Julian |
Director |
|
2021-06-30 |
4 |
B |
$89.74 |
$14,350,692 |
I/I |
155,577 |
12,994,485 |
2.25 |
33% |
|
Baker Julian |
Director |
|
2021-06-29 |
4 |
B |
$89.87 |
$4,892,033 |
I/I |
54,078 |
12,838,908 |
2.25 |
41% |
|
Baker Julian |
Director |
|
2021-06-28 |
4 |
B |
$90.27 |
$4,413,705 |
I/I |
48,274 |
12,784,830 |
2.25 |
40% |
|
Ehrlich Jason |
See Remarks |
|
2021-06-21 |
4 |
AS |
$82.22 |
$590,085 |
D/D |
(6,950) |
60,183 |
|
31% |
|
Ehrlich Jason |
See Remarks |
|
2021-06-15 |
4 |
AS |
$80.90 |
$117,624 |
D/D |
(1,454) |
67,133 |
|
38% |
|
Ehrlich Jason |
See Remarks |
|
2021-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,619 |
68,587 |
|
- |
|
Borgeson John A. |
See Remarks |
|
2021-06-15 |
4 |
AS |
$80.90 |
$104,361 |
D/D |
(1,290) |
170,319 |
|
38% |
|
Borgeson John A. |
See Remarks |
|
2021-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,619 |
171,609 |
|
- |
|
Ehrlich Jason |
See Remarks |
|
2021-06-15 |
4 |
S |
$84.75 |
$97,208 |
D/D |
(1,147) |
64,968 |
|
-38% |
|
Borgeson John A. |
See Remarks |
|
2021-06-15 |
4 |
S |
$84.75 |
$87,886 |
D/D |
(1,037) |
167,990 |
|
-38% |
|
Ehrlich Jason |
See Remarks |
|
2021-06-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,900 |
66,115 |
|
- |
|
Borgeson John A. |
See Remarks |
|
2021-06-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,025 |
169,027 |
|
- |
|
Ehrlich Jason |
See Remarks |
|
2021-05-20 |
4 |
AS |
$80.85 |
$563,924 |
D/D |
(6,950) |
63,161 |
|
21% |
|
98 Records found
|
|
Page 1 of 4 |
|
|